Diabetes

GI adverse events up with GLP-1 receptor agonists

(HealthDay)—Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are associated with increased risk of gastrointestinal adverse events (AEs), with risk varying based on dose, background medications, and type of GLP-1 ...

Diseases, Conditions, Syndromes

Relamorelin beneficial in adults with diabetic gastroparesis

(HealthDay)—For adults with diabetic gastroparesis, relamorelin reduces vomiting frequency and severity and accelerates gastric emptying, according to a study published in the July issue of Gastroenterology.

Oncology & Cancer

Personalized anti-nausea therapy better for cancer patients

A new research study led by Dr. Mark Clemons, oncologist and associate cancer research scientist at The Ottawa Hospital, has shown that a personalized approach to treating one of the most expected side-effects of chemotherapy ...

Other

Cannabis not recommended to prevent post-op nausea

(HealthDay)—Cannabis should not be used to prevent postoperative nausea and vomiting (PONV) because of unacceptable side effects and low effectiveness, according to a study published online Sept. 30 in Anesthesia & Analgesia.

Medications

Anti-nausea drug approved

(HealthDay)—Varubi (rolapitant) has been approved by the U.S. Food and Drug Administration to treat nausea and vomiting among adults undergoing cancer chemotherapy.

page 2 from 10